The Cooper Companies, Inc. $COO Shares Sold by Prudential PLC

Prudential PLC trimmed its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COOFree Report) by 7.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,630 shares of the medical device company’s stock after selling 7,837 shares during the period. Prudential PLC’s holdings in Cooper Companies were worth $7,756,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of COO. Wellington Management Group LLP lifted its position in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after buying an additional 4,756,178 shares in the last quarter. Diamond Hill Capital Management Inc. lifted its position in Cooper Companies by 479.6% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,287,837 shares of the medical device company’s stock valued at $269,471,000 after buying an additional 2,720,594 shares in the last quarter. JANA Partners Management LP acquired a new position in Cooper Companies during the third quarter valued at approximately $166,917,000. Capital World Investors lifted its position in Cooper Companies by 25.7% during the third quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock valued at $723,417,000 after buying an additional 2,159,233 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Cooper Companies by 98.8% during the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after buying an additional 1,683,561 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Trading Up 8.6%

NASDAQ COO opened at $67.34 on Friday. The company’s fifty day simple moving average is $65.09 and its 200-day simple moving average is $74.52. The Cooper Companies, Inc. has a 52 week low of $58.89 and a 52 week high of $89.83. The company has a current ratio of 1.34, a quick ratio of 0.79 and a debt-to-equity ratio of 0.22. The stock has a market cap of $13.14 billion, a P/E ratio of 57.07, a PEG ratio of 1.60 and a beta of 0.87.

Cooper Companies (NASDAQ:COOGet Free Report) last posted its earnings results on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. Cooper Companies had a net margin of 5.57% and a return on equity of 10.85%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the company posted $0.96 earnings per share. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Equities research analysts predict that The Cooper Companies, Inc. will post 4.62 EPS for the current fiscal year.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

  • Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
  • Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
  • Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
  • Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
  • Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
  • Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Analyst Ratings Changes

COO has been the topic of a number of recent research reports. Needham & Company LLC reduced their price target on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday. Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Robert W. Baird reduced their price target on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday. Rothschild & Co Redburn cut shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a research report on Wednesday, March 4th. Finally, KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Cooper Companies presently has an average rating of “Hold” and a consensus price target of $82.64.

Get Our Latest Stock Report on COO

Cooper Companies Company Profile

(Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

Featured Articles

Institutional Ownership by Quarter for Cooper Companies (NASDAQ:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.